Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.
Nelson Spector
Research Funding - Novartis
Nelma Cristina D. Clementino
No relevant relationships to disclose
Pedro Enrique Dorlhiac-Llacer
Research Funding - Novartis
Brian Leber
Honoraria - Novartis
Timothy P. Hughes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis
Francisco Cervantes
Consultant or Advisory Role - ADP; Gilead Sciences; Novartis
Honoraria - Bristol-Myers Squibb; Novartis
Anthony P. Schwarer
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Donna L. Forrest
No relevant relationships to disclose
Suzanne Kamel-Reid
Honoraria - Novartis
Research Funding - Novartis
Israel Bendit
No relevant relationships to disclose
Sandip Acharya
Employment or Leadership Position - Novartis
LaTonya Collins
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Darshan Dalal
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Jeffrey H. Lipton
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva